Skip to main content
    D

    Dr. Reddy’s Laboratories Ltd ADR (RDY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $14.70
    -0.04 (-0.27%)

    Market Cap: $12.29B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Dr. Reddy’s Laboratories Ltd ADR (RDY) Financials: Revenue, Profit and Cash Flow

    Updated Oct 23, 2026. Financial statements from company filings, amounts in INR.

    Dr. Reddy’s Laboratories Ltd ADR reported revenue of INR 353.47B for the fiscal year ended Mar 31, 2026, up 8.6% from the year before. That year, net income was INR 45.09B with a net margin of 12.8%, operating cash flow was INR 56.65B and free cash flow was INR 32.10B. The quarter ended Sep 30, 2026 had revenue of INR 86.59B and net income of INR 9.24B.

    Revenue and Margins

    The operating margin was 13.8% in the fiscal year ended Mar 2026. Over the 9 years to Mar 2026, revenue grew from INR 140.81B, a compound annual rate of 10.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026353.47B+8.6%52.8%13.8%12.8%
    Mar 2025325.54B+16.6%58.5%22.1%17.4%
    Mar 2024279.16B+13.5%58.6%24.3%19.9%
    Mar 2023245.88B+14.7%56.7%23.2%18.3%
    Mar 2022214.39B+8288.8%53.1%13.7%11.0%
    Mar 20212.56B-98.5%50.8%16.9%9.1%
    Mar 2020174.60B+13.5%53.8%9.2%11.2%
    Mar 2019153.85B+8.3%54.2%13.6%12.2%
    Mar 2018142.03B+0.9%53.7%8.4%6.9%
    Mar 2017140.81BN/A55.6%9.6%8.5%
    Annual, fiscal years ended Mar 2017 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, net income fell 20.3% from the year before. In the quarter ended Sep 2026, net income fell 35.7% from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue353.47B325.54B279.16B245.88B214.39B2.56B174.60B153.85B142.03B140.81B
    Cost of revenue166.95B135.11B115.56B106.54B100.55B1.26B80.59B70.42B65.72B62.45B
    Gross profit186.52B190.43B163.61B139.34B113.84B1.30B94.01B83.43B76.30B78.36B
    Research and development25.31B27.38B22.87B19.38B17.48B208.37M15.41B15.61B18.27B19.55B
    Operating income48.87B71.84B67.73B57.14B29.48B431.44M15.99B20.89B11.92B13.50B
    Net income45.09B56.54B55.68B45.07B23.57B232.21M19.50B18.80B9.81B12.04B
    EBITDA83.29B96.67B88.42B74.43B45.08B13.16B41.78B35.52B23.63B24.77B
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue86.59B81.18B76.33B87.27B88.05B85.45B85.06B83.59B80.16B76.73B70.83B72.15B
    Gross profit45.14B37.76B34.22B46.81B48.14B48.63B47.26B49.05B47.77B46.34B41.48B42.20B
    Operating income11.88B2.97B473.25M14.24B17.51B17.48B17.65B18.72B17.55B17.93B14.96B17.27B
    Net income9.24B4.46B2.24B12.10B14.37B14.18B15.94B14.13B12.55B13.92B13.07B13.79B
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, total debt of INR 76.05B exceeded cash and equivalents by 60.99B.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Total assets567.88B492.99B387.52B321.85B292.83B3.63B3.07B225.43B225.60B219.82B
    Current assets296.00B250.11B248.05B204.25B181.86B2.03B1.72B114.50B109.64B100.38B
    Cash and equivalents15.06B14.65B7.11B5.78B14.85B202.82M27.14M2.23B2.64B18.14B
    Total liabilities194.95B155.82B106.97B90.86B102.30B1.26B1.02B85.23B99.14B95.78B
    Short-term debt63.85B38.90B14.03B12.19B28.10B328.38M274.92M16.38B25.63B43.74B
    Long-term debt12.20B3.80B3.80B05.75B6.30B021.45B24.46B4.85B
    Shareholder equity369.60B333.39B280.55B230.99B190.53B2.37B2.05B140.20B126.46B124.04B
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets577.00B575.30B567.88B562.90B542.00B519.54B492.99B481.06B465.95B415.30B387.52B372.84B
    Total liabilities185.92B188.57B194.95B187.14B179.92B165.78B155.82B159.49B156.67B120.67B106.97B104.99B
    Cash and equivalents13.35B11.20B15.06B18.66B9.91B9.00B14.65B12.29B11.33B4.91B7.11B7.34B
    Shareholder equity387.87B383.43B369.60B372.37B358.49B350.06B333.39B317.72B305.34B294.63B280.55B267.85B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Mar 2026, free cash flow was 56.7% of operating cash flow. Dividends came to 21.8% of it.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating cash flow56.65B46.43B45.43B58.87B28.11B35.70B29.84B28.70B18.03B21.51B
    Capital expenditures24.54B34.40B27.43B18.86B19.05B12.56B6.12B7.49B11.04B40.98B
    Free cash flow32.10B12.03B18.00B40.01B9.06B23.14B23.73B21.21B6.99B-19.47B
    Dividends paid7.01B6.66B6.65B4.98B4.15B4.15B3.92B4.00B3.99B3.39B
    Investing cash flow-70.53B-58.08B-40.28B-41.37B-26.39B-22.66B-4.92B-7.73B-14.88B-18.47B
    Financing cash flow13.40B18.91B-3.76B-26.86B-2.42B-298.00M-25.16B-21.33B-4.44B-3.69B
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow4.69B-927.00M15.44B10.91B15.57B14.63B22.00B6.62B9.32B8.50B136.19M4.74B
    Capital expenditures2.39B3.70B4.69B7.32B10.13B10.15B11.25B8.82B7.91B6.42B63.29M5.04B
    Free cash flow2.31B-4.63B10.75B3.59B5.44B4.48B10.75B-2.20B1.41B2.07B72.90M-305.00M
    Last 12 quarters

    Frequently Asked Questions About RDY

    What is Dr. Reddy’s Laboratories Ltd ADR's annual revenue?

    Dr. Reddy’s Laboratories Ltd ADR reported revenue of INR 353.47B for the fiscal year ended Mar 31, 2026.

    How fast is Dr. Reddy’s Laboratories Ltd ADR's revenue growing?

    Revenue was up 8.6% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 12.9%.

    Is Dr. Reddy’s Laboratories Ltd ADR profitable?

    Yes. Dr. Reddy’s Laboratories Ltd ADR reported net income of INR 45.09B for the fiscal year ended Mar 31, 2026, with a net margin of 12.8%.

    How much free cash flow does RDY generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of INR 56.65B minus capital expenditures of INR 24.54B produced free cash flow of INR 32.10B.

    How much debt does Dr. Reddy’s Laboratories Ltd ADR have?

    The balance sheet dated Mar 31, 2026 reported long-term debt of INR 12.20B, short-term debt of INR 63.85B and cash and equivalents of INR 15.06B.